CGON · CG Oncology Inc.
AI read · Good for CGON
The AI's read
The trial gives CG Oncology strong evidence that its bladder-cancer drug can delay cancer returning, with few serious treatment problems reported. The company plans FDA applications in 2027, but the drug is not approved yet. The trial results still make the company's path forward look stronger.